IP Library Granted Patent US 12,564,602
Granted Patent B2
US 12,564,602 · App. 17/691,260 · Granted Mar 3, 2026

Contact lens treating solution

Inventors: Vicki Barniak (Fairport, NY); Catherine Scheuer (West Henrietta, NY); William T. Reindel (Webster, NY); John Michael Duex (Livonia, NY); Andrea E. Siverling (Rochester, NY); Elora Supersad (Rochester, NY)
Assignee: BAUSCH + LOMB IRELAND LIMITED
A61K31/728A01N33/12A01N37/52A01P1/00A61K9/0048A61K47/02A61K47/10A61K47/26A61L12/142A61L12/145A61P27/04C11D1/66C11D1/722C11D3/0078C11D3/046C11D3/2065C11D3/222C11D3/227C11D3/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,602
App. No.
17/691,260
Granted
Mar 3, 2026
Kind
B2
Abstract

A contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.

Claims (42)

1 . A contact lens treating solution, consisting of:

(a) about 0.005 to about 2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof;

(b) about 0.01 to about 1 wt. %, based on the total weight of the contact lens treating solution, of erythritol;

(c) one or more nonionic surfactants;

(d) one or more of sodium chloride and potassium chloride;

(e) one or more buffers;

(f) one or more chelating agents;

(g) one or more antimicrobial agents; and

(h) water.

2 . The contact lens treating solution of claim 1 , consisting of:

(a) about 0.01 to about 0.2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof; and

(b) about 0.05 to about 0.5 wt. %, based on the total weight of the contact lens treating solution, of erythritol.

3 . The contact lens treating solution of claim 1 , wherein the one or more nonionic surfactants are one or more of a poloxamer and a poloxamine.

4 . The contact lens treating solution of claim 1 , consisting of:

about 0.05 to about 5 wt. %, based on the total weight of the contact lens treating solution, of the one or more nonionic surfactants;

about 0.01 to about 5 wt. %, based on the total weight of the contact lens treating solution, of the one or more of sodium chloride and potassium chloride; and

about 0.1 to about 10% (w/w) of the one or more buffers.

5 . The contact lens treating solution of claim 1 , wherein the one or more antimicrobial agents include of one or more biguanide antimicrobial agents and one or more quaternary ammonium antimicrobial agents.

6 . The contact lens treating solution of claim 5 , wherein the one or more biguanide antimicrobial agents are poly (hexamethylene biguanide) and alexidine, and the one or more quaternary ammonium antimicrobial agents are Polyquaternium-1.

7 . The contact lens treating solution of claim 5 , consisting of:

about 0.5 ppm to about 10 ppm, based on total weight of the contact lens treating solution, of the one or more biguanide antimicrobial agents; and

about 0.5 ppm to about 10 ppm, based on total weight of the contact lens treating solution, of the one or more quaternary ammonium antimicrobial agents.

8 . The contact lens treating solution of claim 1 , wherein the contact lens treating solution satisfies the biocidal requirements of a Stand-Alone Procedure for Disinfecting Products.

9 . The contact lens treating solution of claim 1 , in the form of an eye care product or a contact lens care product selected from the group consisting of a contact lens preservative solution, a contact lens cleaning solution, a contact lens rewetting solution and a contact lens multi-purpose solution.

10 . The contact lens treating solution of claim 1 , consisting of:

about 0.05 to about 5 wt. %, based on the total weight of the contact lens treating solution, of the one or more nonionic surfactants;

about 0.01 to about 5 wt. %, based on the total weight of the contact lens treating solution, of the one or more of sodium chloride and potassium chloride;

about 0.1 to about 10% (w/w) of the one or more buffers;

about 0.005% to about 0.05% (w/w) of the one or more chelating agents; and

about 0.5 ppm to about 10 ppm, based on total weight of the contact lens treating solution, of the one or more antimicrobial agents.

11 . The contact lens treating solution of claim 1 , consisting of:

about 0.01 to about 0.2 wt. %, based on the total weight of the contact lens treating solution, of hyaluronic acid or a salt thereof;

about 0.05 to about 0.5 wt. %, based on the total weight of the contact lens treating solution, of erythritol;

about 0.1 to about 2 wt. %, based on the total weight of the contact lens treating solution, of the one or more nonionic surfactants;

about 0.01 to about 5 wt. %, based on the total weight of the contact lens treating solution, of the one or more of sodium chloride and potassium chloride;

about 0.1 to about 10% (w/w) of the one or more buffers;

about 0.005% to about 0.05% (w/w) of the one or more chelating agents; and

about 0.5 ppm to about 10 ppm, based on total weight of the contact lens treating solution, of the one or more antimicrobial agents.

12 . The contact lens treating solution of claim 1 , wherein the one or more chelating agents are ethylenediaminetetraacetic acid (EDTA) or a metal salt thereof, and the one or more antimicrobial agents include poly (hexamethylene biguanide), alexidine, and Polyquaternium-1.

13 . The contact lens treating solution of claim 12 , wherein the one or more nonionic surfactants include one or more of a poloxamer and a poloxamine.

14 . The contact lens treating solution of claim 1 , having an osmolality of about 200 mOsmol/kg to about 400 mOsmol/kg.

15 . The contact lens treating solution of claim 14 , having a pH of about 6 to about 8.

Assignments (11)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (062134/0854) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072976/0492 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Feb 12, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066552/0041 →
PARTIAL RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Mar 3, 2023
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 062945/0360 →
PARTIAL RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Mar 3, 2023
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 062945/0299 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 15, 2022
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 062134/0854 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2022
From: SUPERSAD, ELORA
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061273/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2022
From: BARNIAK, VICKI; SCHEUER, CATHERINE; REINDEL, WILLIAM T.; DUEX, JOHN MICHAEL; GIALLOMBARDO, ANDREA E.
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061010/0540 →
SECURITY INTEREST Recorded Mar 30, 2022
From: BAUSCH+LOMB IRELAND LIMITED; BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; SALIX PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059446/0670 →
SECURITY INTEREST Recorded Mar 30, 2022
From: BAUSCH+LOMB IRELAND LIMITED; BAUSCH HEALTH IRELAND LIMITED; BAUSCH & LOMB INCORPORATED; SALIX PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 059446/0722 →
Continuity (2)
Provisional Application 63159097 · Mar 10, 2021
Related Publication 20220290072A1 · Sep 15, 2022
References Cited (30)
US 4758595A · Ogunbiyi et al. · 1988 [cited by applicant]
US 5573726A · Dassanayake et al. · 1996 [cited by applicant]
US 6180093B1 · De et al. · 2001 [cited by applicant]
US 6517933B1 · Soane et al. · 2003 [cited by applicant]
US 8119112B2 · Xia · 2012 [cited by examiner]
US 8759321B2 · Burke et al. · 2014 [cited by applicant]
US 9096819B2 · Xia · 2015 [cited by examiner]
US 9309357B2 · Awasthi et al. · 2016 [cited by applicant]
US 20030044468A1 · Cellesi et al. · 2003 [cited by applicant]
US 20090196846A1 · Xia et al. · 2009 [cited by applicant]
US 20100286010A1 · Xia et al. · 2010 [cited by applicant]
US 20110046033A1 · Zhang · 2011 [cited by applicant]
US 20120283333A1 · Xia et al. · 2012 [cited by applicant]
US 20140221309A1 · Beard et al. · 2014 [cited by applicant]
US 20180098937A1 · Horn · 2018 [cited by applicant]
US 20200000954A1 · Awasthi et al. · 2020 [cited by applicant]
CN 111518627A · 2020 [cited by applicant]
EP 0929292B1 · 2001 [cited by applicant]
JP 2013006877A · 2013 [cited by applicant]
TH 53397A · 2002 [cited by applicant]
WO 2018071619A1 · 2018 [cited by applicant]
WO PCTEP2022056132 · 2022 [cited by applicant]
Gertjan J.M. den Hartog et. al, Erythritol is a sweet antioxidant, Nutrition, vol. 26, Issue 4, 2010, pp. 449-458, (Year: 2010). [cited by examiner]
Bayhan et al., Effects of osmoprotective eye drops on tear osmolarity in contact lens wearers, 50 Can. J. Ophthalmol. 283-89 (2015). (Year: 2015). [cited by examiner]
Rinaudo, et al. Effect of Mannitol on Hyaluronic Acid Stability in Two in Vitro Models of Oxidative Stress Polymers, (2014) 6, pp. 1948-1957. [cited by applicant]
U.S. Appl. No. 17/691,263, filed Mar. 10, 2022. [cited by applicant]
U.S. Appl. No. 17/691,265, filed Mar. 10, 2022. [cited by applicant]
Japanese Patent Application No. 2023-555213, Office Action dated Oct. 9, 2025, 4 pages. [cited by applicant]
European Patent Application No. 22713899.7, Office Action dated Apr. 16, 2025, 7 pages. [cited by applicant]
Chinese Patent Application No. 202280018795.1, Office Action dated Dec. 27, 2025, 11 pages. [cited by applicant]